Please login to the form below

Not currently logged in
Email:
Password:

drug reimbursement

This page shows the latest drug reimbursement news and features for those working in and with pharma, biotech and healthcare.

Connecting the dots

Connecting the dots

Not just any drug mind you - a decades-old corticosterioid called Emflaza (deflazacort) that is available elsewhere for about $1, 500 per year. ... And, by the way, faster drug approvals are meaningless without reimbursement coverage (something I have

Latest news

  • French pharma growth restricted by generics French pharma growth restricted by generics

    Such government spending funds France's extensive healthcare reimbursement system, which sees the state health system pay money back into citizens' accounts after they have paid for a service, such as ... If a drug is approved for reimbursement it will

  • No further price cut for non-PPRS drugs in UK No further price cut for non-PPRS drugs in UK

    The DH announced in November 2013 that it would reduce the cost of these statutory medicines by 15% as part of wider drug pricing negotiations and there were concerns that this ... Also weighing in was the Ethical Medicines Industry Group, representing

  • No further price cut for non-PPRS drugs in UK No further price cut for non-PPRS drugs in UK

    The DH announced in November 2013 that it would reduce the cost of these statutory medicines by 15% as part of wider drug pricing negotiations and there were concerns that this ... Also weighing in was the Ethical Medicines Industry Group, representing

  • Janssen will cover cost of unsuccessful hepatitis C treatment Janssen will cover cost of unsuccessful hepatitis C treatment

    Both Olysio and Sovaldi were this week recommended for NHS reimbursement in draft guidance published by the National Institute for Health and Care Excellence (NICE). ... The drug is relatively pricey, costing £27, 220 or £32, 155 as part of a regimen

  • Pharma condemns Cancer Drugs Fund cuts Pharma condemns Cancer Drugs Fund cuts

    Company. Drug. Area of indication. Bayer. Stivarga (regorafenib). Gastro-intestinal stromal. tumours (GIST). ... However, Dr Dallas added that a wider reform of cancer drug reimbursement in the UK was needed and the country can't rely on the CDF as a long

More from news
Approximately 38 fully matching, plus 63 partially matching documents found.

Latest Intelligence

  • When science is not enough When science is not enough

    a drug’s chances of reimbursement. ... BEACON makes it easier for different stakeholders to communicate during a drug’s development.

  • Market access improvements in Turkey Market access improvements in Turkey

    In 2015 there were 8, 104 products on the reimbursement list, with 292 new ones added. ... Reimbursement pricing. A decree on drug pricing (2015/7752) appeared in July 2015 and was implemented by a communiqué last December.

  • Making savings from European drugs budgets Making savings from European drugs budgets

    Assessing value in Sweden, Germany and the UK. Sofia Wollstrom, director-general of the Dental and Pharmaceutical Benefits Agency (which decides on drug pricing and reimbursement in Sweden), told PME that ... GBA [which has the final say on drug

  • Turkey's pharma market is ripe for profitability Turkey's pharma market is ripe for profitability

    Koçsel. This new production facility could take Turkey into the realms of leading the global oncological drug field through the 184 different products that it seeks to develop in its portfolio.

  • Allergan and taking a specialised approach Allergan and taking a specialised approach

    This approach makes it easier when it comes to the reimbursement stage of drug development, which has proven to be a cause of concern for many companies who struggle to gain ... Both Navarre and Boland agree it's a drug the company is very proud of, but

More from intelligence
Approximately 7 fully matching, plus 14 partially matching documents found.

Latest appointments

  • Extension for head of Germany’s VFA Extension for head of Germany’s VFA

    She has led the industry voice during an unsettled time for pharma in Germany with many companies critical of the AMNOG system of drug reimbursement introduced in 2010, which has seen

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics